August 2, 2021
Takeda Pharmaceutical’s NEDD8-activating enzyme inhibitor pevonedistat cleared a key health ministry panel on July 30 for sakigake fast-track designation, opening the way for it to be the first drug to gain the status since the scheme earned full legal backing...read more